Latest research on Pregabalin

Pregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica. It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S. [Wikipedia]

Pregabalin and alcohol

These substances included Amphetamine (two cases), 3-methylmethcathinone (two cases), a metabolite of KETAMINE, alcohol, buprenorphine, and drugs such as benzodiazepines (Alprazolam, Diazepam, nordazepam, pyrazolam), Pregabalin, Gabapentin, Zopiclone, Mirtazapine, Paroxetine, Bupropion, and Aripiprazole. [source, 2015]
Pregabalin has also been proposed as a treatment option for withdrawal symptoms in alcohol, benzodiazepine and, more recently, opioid dependence, but this use is not supported by Level I clinical evidence and remains controversial.32,33 [source, 2015]
Treatment began once alcohol and benzodiazepine intake were excluded via laboratory screening tests administered through the course of rTMS, with antidepressant (75 mg Amitriptyline) and antiepileptic (150–300 mg Pregabalin) dosage kept constant throughout treatment. [source, 2015]
The issue that alcohol can reduce one’s inhibitions to actually carry out suicidal ideations should be separately addressed in the dialogue with the patient and the combination with Pregabalin should strictly be advised against. [source, 2014]
Pregabalin has an abuse liability because it produces the disturbances in central nervous system [83] and therefore, it needs careful administration in patients with alcohol and benzodiazepine dependence [84]. [source, 2014]
Administration of Pregabalin with alcohol or benzodiazepines may synergistically depress neuronal conduction in the CNS possibly due to the enhancement of GABA mediated actions and inhibition of Ca2+ mediated glutamate release at synapses [85]. [source, 2014]
Inclusion criteria were (1) currently meeting DSM- IV-TR [16] criteria for anxiety disorder (38 patients), alcohol dependence (30 patients), or pathological gambling (35 patients); (2) having an age of 18 to 65 years; (3) for the anxious patients, spending at least one month of integrated treatments including benzodiazepines and/or selective serotonin reuptake inhibitors-serotonin norepinephrine reuptake inhibitors (SSRI-SNRI); (4) for the alcoholics and gamblers, spending at least one month of a specific rehabilitation program requiring total abstinence from the addictive behavior (alcohol abuse or pathological gambling) and the possibility, upon the clinician's advice, of a maintenance treatment with mood stabilizers (valproate, Gabapentin, and Pregabalin). [source, 2014]
In addition, Pregabalin has been extensively studied in alcohol and benzodiazepine dependence [59]. [source, 2014]
In addition, preclinical studies in animal models indicate that Pregabalin reduces alcohol consumption and alcohol-seeking behavior,119 and reduces the severity of handling-induced seizures in mice withdrawing from alcohol. [source, 2013]
The evidence that Pregabalin facilitates alcohol withdrawal symptoms and the maintenance of abstinence in detoxified patients is encouraging but inconsistent.121 [source, 2013]